161 related articles for article (PubMed ID: 31520321)
41. Biguanide-Based Synthesis of 1,3,5-Triazine Derivatives with Anticancer Activity and 1,3,5-Triazine Incorporated Calcium Citrate Nanoparticles.
Chalermnon M; Cherdchom S; Sereemaspun A; Rojanathanes R; Khotavivattana T
Molecules; 2021 Feb; 26(4):. PubMed ID: 33672071
[TBL] [Abstract][Full Text] [Related]
42. Synthesis and antitumor activity of benzimidazolyl-1,3,5-triazine and benzimidazolylpyrimidine derivatives.
Matsuno T; Karo M; Sasahara H; Watanabe T; Inaba M; Takahashi M; Yaguchi SI; Yoshioka K; Sakato M; Kawashima S
Chem Pharm Bull (Tokyo); 2000 Nov; 48(11):1778-81. PubMed ID: 11086914
[TBL] [Abstract][Full Text] [Related]
43. A new triazine based π-conjugated mesoporous 2D covalent organic framework: its in vitro anticancer activities.
Kanti Das S; Mishra S; Manna K; Kayal U; Mahapatra S; Das Saha K; Dalapati S; Das GP; Mostafa AA; Bhaumik A
Chem Commun (Camb); 2018 Oct; 54(81):11475-11478. PubMed ID: 30256355
[TBL] [Abstract][Full Text] [Related]
44. Synthesis of Arylamino-1,3,5-triazines Functionalized with Alkylatin 2-chloroethylamine Fragments and Studies of their Cytotoxicity on the Breast Cancer MCF-7 Cell Line.
Fraczyk J; Kolesinska B; Swiontek M; Lipinski W; Drozdowska D; Kaminski ZJ
Anticancer Agents Med Chem; 2016; 16(11):1435-1444. PubMed ID: 26845131
[TBL] [Abstract][Full Text] [Related]
45. Inhibition of proliferation and induction of apoptosis by genistein in colon cancer HT-29 cells.
Yu Z; Li W; Liu F
Cancer Lett; 2004 Nov; 215(2):159-66. PubMed ID: 15488634
[TBL] [Abstract][Full Text] [Related]
46. Novel diosgenin derivatives containing 1,3,4-oxadiazole/thiadiazole moieties as potential antitumor agents: Design, synthesis and cytotoxic evaluation.
Zhang J; Wang X; Yang J; Guo L; Wang X; Song B; Dong W; Wang W
Eur J Med Chem; 2020 Jan; 186():111897. PubMed ID: 31761382
[TBL] [Abstract][Full Text] [Related]
47. Synthesis and Antitumor Evaluation in Vitro of NO-Donating Ursolic Acid-Benzylidene Derivatives.
Zhang T; He B; Yuan H; Feng G; Chen F; Wu A; Zhang L; Lin H; Zhuo Z; Wang T
Chem Biodivers; 2019 Jun; 16(6):e1900111. PubMed ID: 30977577
[TBL] [Abstract][Full Text] [Related]
48. Quinazoline clubbed 1,3,5-triazine derivatives as VEGFR2 kinase inhibitors: design, synthesis, docking, in vitro cytotoxicity and in ovo antiangiogenic activity.
Pathak P; Shukla PK; Kumar V; Kumar A; Verma A
Inflammopharmacology; 2018 Dec; 26(6):1441-1453. PubMed ID: 29663100
[TBL] [Abstract][Full Text] [Related]
49. Deciphering the molecular mechanism and apoptosis underlying the in-vitro and in-vivo chemotherapeutic efficacy of vanadium luteolin complex in colon cancer.
Roy S; Chakraborty T
Cell Biochem Funct; 2018 Apr; 36(3):116-128. PubMed ID: 29574863
[TBL] [Abstract][Full Text] [Related]
50. Structure-based design and synthesis of novel macrocyclic pyrazolo[1,5-a] [1,3,5]triazine compounds as potent inhibitors of protein kinase CK2 and their anticancer activities.
Nie Z; Perretta C; Erickson P; Margosiak S; Lu J; Averill A; Almassy R; Chu S
Bioorg Med Chem Lett; 2008 Jan; 18(2):619-23. PubMed ID: 18055206
[TBL] [Abstract][Full Text] [Related]
51. Novel enmein-type diterpenoid hybrids coupled with nitrogen mustards: Synthesis of promising candidates for anticancer therapeutics.
Gao X; Li J; Wang M; Xu S; Liu W; Zang L; Li Z; Hua H; Xu J; Li D
Eur J Med Chem; 2018 Feb; 146():588-598. PubMed ID: 29407983
[TBL] [Abstract][Full Text] [Related]
52. Target identification, lead optimization and antitumor evaluation of some new 1,2,4-triazines as c-Met kinase inhibitors.
El-Wakil MH; Ashour HM; Saudi MN; Hassan AM; Labouta IM
Bioorg Chem; 2017 Aug; 73():154-169. PubMed ID: 28715754
[TBL] [Abstract][Full Text] [Related]
53. Synthesis, Characterization, Antimicrobial Activity and Anticancer of Some New Pyrazolo[1,5-a]pyrimidines and Pyrazolo[5,1-c]1,2,4-triazines.
Hosny MA; Zaki YH; Mokbel WA; Abdelhamid AO
Med Chem; 2020; 16(6):750-760. PubMed ID: 31218963
[TBL] [Abstract][Full Text] [Related]
54. Synthesis, structure and anticancer activity of novel 2,4-diamino-1,3,5-triazine derivatives.
Saczewski F; Bułakowska A; Bednarski P; Grunert R
Eur J Med Chem; 2006 Feb; 41(2):219-25. PubMed ID: 16377034
[TBL] [Abstract][Full Text] [Related]
55. Design, synthesis, docking studies and biological evaluation of novel dihydro-1,3,5-triazines as human DHFR inhibitors.
Zhou X; Lin K; Ma X; Chui WK; Zhou W
Eur J Med Chem; 2017 Jan; 125():1279-1288. PubMed ID: 27886545
[TBL] [Abstract][Full Text] [Related]
56. Quinazoline based 1,3,5-triazine derivatives as cancer inhibitors by impeding the phosphorylated RET tyrosine kinase pathway: Design, synthesis, docking, and QSAR study.
Pathak P; Naumovich V; Grishina M; Shukla PK; Verma A; Potemkin V
Arch Pharm (Weinheim); 2019 Sep; 352(9):e1900053. PubMed ID: 31380598
[TBL] [Abstract][Full Text] [Related]
57. Targeting FLIP and Mcl-1 using a combination of aspirin and sorafenib sensitizes colon cancer cells to TRAIL.
Pennarun B; Kleibeuker JH; Boersma-van Ek W; Kruyt FA; Hollema H; de Vries EG; de Jong S
J Pathol; 2013 Feb; 229(3):410-21. PubMed ID: 23132258
[TBL] [Abstract][Full Text] [Related]
58. Microwave assisted synthesis of some new fused 1,2,4-triazines bearing thiophene moieties with expected pharmacological activity.
Saad HA; Youssef MM; Mosselhi MA
Molecules; 2011 Jun; 16(6):4937-57. PubMed ID: 21677606
[TBL] [Abstract][Full Text] [Related]
59. Design, synthesis and biological evaluation of novel N-[4-(2-fluorophenoxy)pyridin-2-yl]cyclopropanecarboxamide derivatives as potential c-Met kinase inhibitors.
Liu J; Gong Y; Shi J; Hao X; Wang Y; Zhou Y; Hou Y; Liu Y; Ding S; Chen Y
Eur J Med Chem; 2020 May; 194():112244. PubMed ID: 32224380
[TBL] [Abstract][Full Text] [Related]
60. Convenient synthesis of fused heterocyclic 1,3,5-triazines from some N-acyl imidates and heterocyclic amines as anticancer and antioxidant agents.
Bekircan O; Küxük M; Kahveci B; Kolayli S
Arch Pharm (Weinheim); 2005 Aug; 338(8):365-72. PubMed ID: 16041836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
